In the News
Boost for Alzheon’s targeted Alzheimer’s candidate
thepharmaletter.com
Neurodegenerative Treatments Build to a Tipping Point
Genetic Engineering & Biotechnology News (GEN)
Take A Pill For It! Approach to Alzheimer’s Disease
Bloomer Boomer
Press Releases
Alzheon Reports Industry-Leading Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
29% Reduction in Plasma P-tau181, Core Biomarker of Alzheimer’s Pathology, Observed after 6 Months Treatment in Carriers of One or Two Copies of APOE4 Gene who Represent Two Thirds of Patients with Disease
Alzheon to Present at H.C. Wainwright Bioconnect Conference on January 10, 2022
Alzheon CEO Dr. Martin Tolar Will Provide Overview of Company Business and Update on Oral Anti-Amyloid ALZ-801 Phase 3 Program in Alzheimer’s Disease
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference
Baseline Data in Early Alzheimer’s Disease Shows Significant Differences in CSF Biomarker Profiles Between APOE4/4 Homozygotes and APOE3/4 Heterozygotes Validating Patient Selection for APOLLOE4 Phase 3 Study with ALZ-801 Tablet
Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021
Alzheon CEO Dr. Martin Tolar Will Provide Overview of Company Business and Update on Oral Anti-Amyloid ALZ-801 Phase 3 Program in Alzheimer’s Disease
Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development
New Hires Bring Extensive Precision Medicine and Clinical Development Expertise as Alzheon Advances Phase 2 & 3 Trials of ALZ-801 Tablet in Alzheimer’s Disease
Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease
Study Evaluates Biomarker Evidence of Disease Modification in APOE4 Carriers, Who Comprise Two-Thirds of All Alzheimer’s Patients